Lilly Expects Zyprexa Sales To Flatten During Bristol Abilify Launch In Q4
Lilly is preparing for a temporary slowdown in Zyprexa growth during the introduction of Bristol-Myers Squibb's schizophrenia drug Abilify
Lilly is preparing for a temporary slowdown in Zyprexa growth during the introduction of Bristol-Myers Squibb's schizophrenia drug Abilify